ET190L1-Artemis™ Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma

被引:1
|
作者
Ying, Zhitao [1 ]
Long, Li [2 ]
Liu, Hong [3 ]
Song, Yuqin [1 ]
Rizzieri, David A. [4 ,5 ]
Nejadnik, Bijan [6 ]
Zhu, Jun [1 ]
Liu, Cheng [3 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma,Minist Educ, Beijing, Peoples R China
[2] Eureka Therapeut Inc, Lafayette, CA USA
[3] Eureka Therapeut Inc, Emeryville, CA USA
[4] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA
[5] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA
[6] Eureka Therapeut Inc, Clin Dev, Emeryville, CA USA
关键词
D O I
10.1182/blood-2018-99-113163
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1689
引用
收藏
页数:3
相关论文
共 50 条
  • [41] DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL)
    Shustov, A.
    Advani, R.
    Brice, P.
    Bartlett, N. L.
    Rosenblatt, J. D.
    Illidge, T.
    Matous, J.
    Ramchandren, R.
    Fanale, M.
    Connors, J. M.
    Yang, Y.
    Sievers, E. L.
    Kennedy, D. A.
    Pro, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 125 - 125
  • [42] Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
    Hutchings, Martin
    Morschhauser, Franck
    Iacoboni, Gloria
    Carlo-Stella, Carmelo
    Offner, Fritz C.
    Sureda, Anna
    Salles, Gilles
    Martinez-Lopez, Joaquin
    Crump, Michael
    Thomas, Denise N.
    Morcos, Peter N.
    Ferlini, Cristiano
    Broeske, Ann-Marie E.
    Belousov, Anton
    Bacac, Marina
    Dimier, Natalie
    Carlile, David J.
    Lundberg, Linda
    Perez-Callejo, David
    Umana, Pablo
    Moore, Tom
    Weisser, Martin
    Dickinson, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 1959 - +
  • [43] Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
    Karimi, Yasmin
    Ghesquieres, Herve
    Jurczak, Wojciech
    Cheah, Chan
    Clausen, Michael
    Lugtenburg, Pieternella
    Cunningham, David
    Do, Young Rok
    Lewis, David John
    Gasiorowski, Robin
    Kim, Tae Min
    Van der Poel, Marjolein
    Poon, Michelle Li Mei
    Feldman, Tatyana A.
    Linton, Kim M.
    Sureda, Anna
    Hutchings, Martin
    Stirner, Mariana Cota
    Sacchi, Mariana
    Thieblemont, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] NEUROTOXICITY ASSOCIATED WITH CAR-T THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. EXPERIENCE OF A CENTER
    Borja, Puertas
    Monica, Alana
    Lopez Estefania, Perez
    Ana Africa, Martin Lopez
    Jesus Alberto, Vizcaya
    Maria Carmen, Montes Gonzalo
    Ubeda Sandra, Gomez
    Sanchez Alberto, Hernandez
    Luz Gema, Roman Molano
    Munoz Felipe, Pena
    Mendoza Danylo, Palomino
    Laura, Prieto
    Parra Miriam, Lopez
    Pilar, Tamayo
    Gutierrez Norma, Gutierrez
    Garcia-Sancho Alejandro, Martin
    Fermin, Sanchez-Guijo
    Maria Dolores, Caballero Barrigon
    Noelia, Albala
    Corral Lucia, Lopez
    HAEMATOLOGICA, 2021, 106 (10) : 262 - 263
  • [45] Cytopenia after CAR-T cell therapy: Analysis of 63 patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Qiu, Tingting
    Hu, Luan
    Zhang, Yongtian
    Wang, Ying
    Ma, Sha
    Li, Depeng
    Li, Zhenyu
    Xu, Kailin
    ONCOLOGY LETTERS, 2023, 26 (02)
  • [46] Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
    Skalt, Daniela
    Moertl, Bernhard
    von Bergwelt-Baildon, Michael
    Schmidt, Christian
    Schoel, Wolfgang
    Buecklein, Veit
    Weiglein, Tobias
    Dreyling, Martin
    Berger, Karin
    HEMASPHERE, 2022, 6 (07): : E736
  • [47] Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Lin, Richard J.
    Lobaugh, Stephanie M.
    Pennisi, Martina
    Chan, Jason T.
    Batlevi, Yakup
    Ruiz, Josel D.
    Elko, Theresa A.
    Maloy, Molly A.
    Batlevi, Connie Lee
    Dahi, Parastoo B.
    Giralt, Sergio A.
    Mead, Elena
    Noy, Ariela
    Palomba, Maria Lia
    Santomasso, Bianca
    Sauter, Craig S.
    Scordo, Michael
    Shah, Gunjan L.
    Korc-Grodzicki, Beatriz
    Kim, Soo Jung
    Silverberg, Mari Lynne
    Brooklyn, Chelsea A.
    Devlin, Sean M.
    Perales, Miguel-Angel
    BLOOD, 2019, 134
  • [48] Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma
    Chihara, Dai
    Liao, Laura
    Tkacz, Joseph
    Franco, Anjali
    Lewing, Benjamin
    Kilgore, Karl M.
    Nastoupil, Loretta J.
    Chen, Lei
    BLOOD, 2023, 142 (12) : 1047 - 1055
  • [49] Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Lin, Richard J.
    Lobaugh, Stephanie M.
    Pennisi, Martina
    Chan, Hei Ton
    Batlevi, Yakup
    Ruiz, Josel D.
    Elko, Theresa A.
    Maloy, Molly A.
    Batlevi, Connie L.
    Dahi, Parastoo B.
    Hamlin, Paul A.
    Giralt, Sergio A.
    Hamlin, Paul A.
    Mead, Elena
    Noy, Ariela
    Palomba, M. Lia
    Santomasso, Bianca D.
    Sauter, Craig S.
    Scordo, Michael
    Shah, Gunjan L.
    Korc-Grodzicki, Beatriz
    Kim, Soo Jung
    Silverberg, Mari Lynne
    Brooklyn, Chelsea A.
    Devlin, Sean M.
    Perales, Miguel-Angel
    HAEMATOLOGICA, 2021, 106 (01) : 255 - 258
  • [50] Multi -Institutional Update on Bridging Radiotherapy in Relapsed or Refractory Large B-Cell Lymphoma Patients Prior to CAR T-Cell Therapy
    Ababneh, H.
    Ng, A.
    Frigault, M. J.
    Jacobson, C.
    Patel, C. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E606 - E606